Keros Therapeutics, Inc.

Keros Therapeutics, Inc. (KROS) priced its initial public offering on Apr 8, 2020 at $16.00 per share, raising $96M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $307M. Jefferies was lead-left underwriter, joined by Leerink Partners, Piper Sandler and H.C. Wainwright. Cooley advised the company and Latham & Watkins advised the underwriters.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for hematological and musculoskeletal disorders, based on its understanding of the TGF-beta family of proteins. Its lead protein therapeutic candidate, KER-050, is being developed for low blood cell counts.

Status

IPO

Ticker

KROS

Exchange

Nasdaq Global Market

Priced

Apr 8, 2020

IPO price

$16.00

Raised

$96M

Market cap at IPO price

$307M

First filed

Mar 16, 2020

Underwriters

Jefferies, Leerink Partners, Piper Sandler and H.C. Wainwright

Company counsel

Cooley

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.